Method of treatment of Hypoxia Inducible Factor (HIF)-related conditions
View Patent ↗The present invention relates to methods of treatment of Hypoxia Inducible Factor (HIF)-related conditions, and in particular to methods of treatment of HIF-related conditions comprising the administration of a composition comprising transferrins.
1. A method of treating a Hypoxia Inducible Factor (HIF)-related pathological condition in a patient in need thereof, wherein the HIF-related pathological condition is Middle Cerebral Artery occlusion (MCAo), comprising administering to the patient a composition comprising a therapeutically effective amount of transferrin, and wherein the transferrin is a mixture of apo-transferrin and holo-transferrin in a ratio from 99% Apo-Tf:1% Holo-Tf to 30% Apo-Tf:70% Holo-Tf.
2. The method of claim 1 , wherein the composition further comprises an iron chelator or prolyl hydroxylase domain-containing protein 2 (PHD2) enzyme inhibitor.
3. The method of claim 2 , wherein the iron chelator is selected from the group consisting of M30, deferoxamine (DFO), Deferasirox, deferiprone, deferitrin, L1NAll, CP363, CP502 and Ethylenediaminetetraacetic acid (EDTA).
4. The method of claim 2 , wherein the PHD2 enzyme inhibitor is selected from the group consisting of IOX2, IOX3 and dimethyloxallylglycine.
5. The method of claim 1 , wherein the patient is a transplant recipient of an organ.
6. The method of claim 5 , wherein the organ has been treated with the composition in preparation for the transplantation into the recipient.
7. The method of claim 6 , where the composition further comprises an iron chelator or prolyl hydroxylase domain-containing protein 2 (PHD2) enzyme inhibitor.
8. The method of claim 1 , wherein the condition is associated with ischemia or oxygen deprivation in the patient prior to surgery.
9. The method of claim 8 , wherein the ischemia is due to cardiac arrest, thrombotic clots, traumatic injury or stroke.
10. The method of claim 1 , wherein the condition is associated with interruption of blood flow during a surgical intervention in the patient.
11. The method of claim 1 , wherein the transferrin is recombinant.
12. The method of claim 1 , wherein the transferrin is modified by pegylation, glycosylation or polysialylation to extend its plasma half-life.
13. The method of claim 1 , wherein the composition further comprises an iron chelator.